PhysQuiz on ASCO GU: Renal Carcinoma

1) Results released from the Phase 3 CLEAR Trial found that lenvatinib combined with EITHER of these two drugs demonstrated significant benefits over sunitinib in patients with advanced RCC:*

a) pembrolizumab or atezolizumab
b) pembrolizumab or everolimus
c) pembrolizumab or nivolumab
d) pembrolizumab or axitinib

2) Extended follow-up results from Phase III JAVELIN (avelumab + axitinib vs sunitinib) in elderly patients with advanced RCC demonstrated a reduction in efficacy and safety profile for patients over the age of 75 years.*

a) True
b) False

3) Results from the NAXIVA trial evaluating the effect of axitinib on venous tumor thrombus in RCC found what positive response rate, with potential to reduce invasive surgery?*

a) 10%
b) 20%
c) 30%
d) 40%

4) Given that there is no optimal therapy for metastatic pRCC, a study comparing standard sunitinib, to putative MET kinase inhibitors found that what treatment achieved significant prolongation of PFS?*

a) sunitinib
b) crizotinib
c) savolitinib
d) cabozantinib

CAPTCHA

Follow Us

PhysQuiz on ASCO GU: Renal Carcinoma

Author